Cartilage Degeneration – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Cartilage Degeneration – Drugs In Development, 2024 report and make more profitable business decisions.
Cartilage is a connective tissue of bone that protects bones and joints. Degeneration or destruction of cartilage results from both synovial-dependent and synovial-independent processes. Synovial fluid present in joints acts as a shock observer and a lubricant. Cartilage degeneration is commonly seen in osteoarthritis. OA is a degenerative inflammatory joint disease where the tissue in the joints breaks down overtime. Joint pain in hands/fingers, knees, neck, back and in hips, joint stiffness, swelling in and around the joint are the common symptoms. Age, trauma, or injury or fall, underlying diseased conditions, overweight are the common causes and is diagnosed by X-ray, MRI, other laboratory tests, physical examination to assess pain level, redness, swelling, RA factor to differentiate from rheumatoid arthritis. NSAIDS are the first line therapy for OA followed by non-pharmacological ways like hot and cold packs to relieve pain. Surgical options are chosen in complicated cases where hip replacement, knee replacement or joint replacement done.
The Cartilage Degeneration drugs in development market research report provide comprehensive information on the therapeutics under development for Cartilage Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cartilage Degeneration and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Cartilage Degeneration | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 14 molecules, with 11 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Cartilage Degeneration therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Cartilage Degeneration pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Cartilage Degeneration treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AbelZeta IncBioinova sro
Cellatoz Therapeutics Inc
Daewoong Pharmaceutical Co Ltd
Eluciderm Inc
Emory University
Eskisehir Osmangazi University
Generium
Hirosaki Li Co Ltd
Mesoblast Ltd
Tego Science Inc
Turn Biotechnologies Inc
University of California Los Angeles
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Cartilage Degeneration reports